文献速递妇科

隐藏于表象之下——复发性卵巢癌女性基线症状负担的生存后果

Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2024-02-26

该研究分析了948例复发性卵巢癌患者化疗前的基线症状负担,发现约80%报告轻至重度疼痛、90%报告疲乏、89%报告至少1种中重度症状;较高的症状负担与显著缩短的无进展生存期和总生存期相关。作者认为症状负担应积极管理并用于临床试验分层。

要点

  • 复发性卵巢癌患者化疗前普遍存在高基线症状负担,近80%报告疼痛、90%报告疲乏。
  • 89%报告至少1种中重度症状,59%报告6种及以上中重度症状。
  • 较高症状负担与显著缩短的无进展生存期和总生存期相关,5种症状的OS风险比大于2。

核心结论

  • 复发性卵巢癌患者在开始姑息性化疗前报告高症状负担,在铂耐药/难治性复发性卵巢癌与可能铂敏感且接受三线及以上化疗的复发性卵巢癌之间相似。
  • 高症状负担与早期进展和死亡强烈相关。
  • 症状负担应被积极管理并用于临床试验中的患者分层。
  • 临床试验应测量并报告症状负担及治疗对症状控制的影响。

研究设计与样本

  • 研究纳入参加妇科癌症协作组-症状获益研究(GCIG-SBS)的948例患者,包括铂耐药/难治性复发性卵巢癌(PRR-ROC)或接受三线及以上化疗的可能铂敏感复发性卵巢癌(PPS-ROC≥3)。
  • 使用卵巢症状与治疗关注度量表(MOST)分析患者报告的基线症状负担,并将基线症状严重程度与无进展生存期和总生存期进行相关性分析。

主要发现

  • 948例患者报告了显著的基线症状负担:近80%报告轻至重度疼痛,75%报告腹部症状,60%报告气短,90%报告疲乏。
  • 约50%报告中度至重度焦虑,35%报告中度至重度抑郁。
  • 89%报告至少1种症状为中度或重度,59%报告6种及以上症状为中度或重度,46%报告9种及以上症状为中度或重度。
  • 较高的症状负担与显著缩短的无进展生存期和总生存期相关;5种症状(进食困难、呕吐、消化不良、食欲丧失、恶心)在中度和重度症状截断值下总生存期风险比均大于2(p < 0.001)。

临床怎么用

  • 作者认为症状负担应被积极管理,并用于临床试验中的患者分层。
  • 作者认为临床试验应测量并报告症状负担及治疗对症状控制的影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the baseline symptom burden(SB) experienced by patients(pts) with recurrent ovarian cancer(ROC) prior and associations with progression free survival (PFS) and overall survival (OS). METHODS: We analysed baseline SB reported by pts. with platinum resistant/refractory ROC (PRR-ROC) or potentially‑platinum sensitive ROC receiving their third or greater line of chemotherapy (PPS-ROC≥3) enrolled in the Gynecologic Cancer InterGroup - Symptom Benefit Study (GCIG-SBS) using the Measure of Ovarian Symptoms and Treatment concerns (MOST). The severity of baseline symptoms was correlated with PFS and OS. RESULTS: The 948 pts. reported substantial baseline SB. Almost 80% reported mild to severe pain, and 75% abdominal symptoms. Shortness of breath was reported by 60% and 90% reported fatigue. About 50% reported moderate to severe anxiety, and 35% moderate to severe depression. Most (89%) reported 1 or more symptoms as moderate or severe, 59% scored 6 or more symptoms moderate or severe, and 46% scored 9 or more symptoms as moderate or severe. Higher SB was associated with significantly shortened PFS and OS; five symptoms had OS hazard ratios larger than 2 for both moderate and severe symptom cut-offs (trouble eating, vomiting, indigestion, loss of appetite, and nausea; p < 0.001). CONCLUSION: Pts with ROC reported high SB prior to starting palliative chemotherapy, similar among PRR-ROC and PPS-ROC≥3. High SB was strongly associated with early progression and death. SB should be actively managed and used to stratify patients in clinical trials. Clinical trials should measure and report symptom burden and the impact of treatment on symptom control.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Roncolato F, King MT, O'Connell RL, et al. Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer. Gynecol Oncol. 2024. PMID: 38412736. doi:10.1016/j.ygyno.2024.02.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。